Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kyriakos E Kypreos

Showing results (1-10 of 71) with videos related to

Pageof 8
Sort By:
The FEBS Journal|September 17, 2009
Mechanisms of obesity and related pathologiesKyriakos E Kypreos
Biochemistry|September 5, 2008
ABCA1 promotes the de novo biogenesis of apolipoprotein CIII-containing HDL particles in vivo and modulates the severity of apolipoprotein CIII-induced hypertriglyceridemiaKyriakos E Kypreos
Atherosclerosis|September 28, 2010
Testosterone and cardiovascular disease: an old idea with modern clinical implicationsAbdulmaged M Traish, Kyriakos E Kypreos
The Biochemical Journal|January 9, 2007
Pathway of biogenesis of apolipoprotein E-containing HDL in vivo with the participation of ABCA1 and LCATKyriakos E Kypreos, Vassilis I Zannis
Journal of Lipid Research|December 13, 2005
LDL receptor deficiency or apoE mutations prevent remnant clearance and induce hypertriglyceridemia in miceKyriakos E Kypreos, Vassilis I Zannis
Biochemical Pharmacology|September 19, 2012
Pharmacodynamic and pharmacokinetic analysis of apoE4 [L261A, W264A, F265A, L268A, V269A], a recombinant apolipoprotein E variant with improved biological propertiesAngeliki Lampropoulou, Vassilis I Zannis, Kyriakos E Kypreos
Biochemistry|July 28, 2007
Residues Leu261, Trp264, and Phe265 account for apolipoprotein E-induced dyslipidemia and affect the formation of apolipoprotein E-containing high-density lipoproteinKonstantinos Drosatos, Kyriakos E Kypreos, Vassilis I Zannis
Vascular Pharmacology|October 13, 2009
Androgen deficiency and atherosclerosis: The lipid linkAbdulmaged M Traish, Rami Abdou, Kyriakos E Kypreos
Frontiers in Oncology|April 12, 2021
The Lipoprotein Transport System in the Pathogenesis of Multiple Myeloma: Advances and ChallengesVasileios Lazaris, Aikaterini Hatziri, Argiris Symeonidis, et al.
Biochemical Pharmacology|March 19, 2013
HDL particle functionality as a primary pharmacological target for HDL-based therapiesKyriakos E Kypreos, Spyridon Gkizas, Loukianos S Rallidis, et al.
Pageof 8

Showing results (1-10 of 71) with videos related to

Sort By:
Pageof 8
The FEBS Journal|September 17, 2009
Mechanisms of obesity and related pathologiesKyriakos E Kypreos
Biochemistry|September 5, 2008
ABCA1 promotes the de novo biogenesis of apolipoprotein CIII-containing HDL particles in vivo and modulates the severity of apolipoprotein CIII-induced hypertriglyceridemiaKyriakos E Kypreos
Atherosclerosis|September 28, 2010
Testosterone and cardiovascular disease: an old idea with modern clinical implicationsAbdulmaged M Traish, Kyriakos E Kypreos
The Biochemical Journal|January 9, 2007
Pathway of biogenesis of apolipoprotein E-containing HDL in vivo with the participation of ABCA1 and LCATKyriakos E Kypreos, Vassilis I Zannis
Journal of Lipid Research|December 13, 2005
LDL receptor deficiency or apoE mutations prevent remnant clearance and induce hypertriglyceridemia in miceKyriakos E Kypreos, Vassilis I Zannis
Biochemical Pharmacology|September 19, 2012
Pharmacodynamic and pharmacokinetic analysis of apoE4 [L261A, W264A, F265A, L268A, V269A], a recombinant apolipoprotein E variant with improved biological propertiesAngeliki Lampropoulou, Vassilis I Zannis, Kyriakos E Kypreos
Biochemistry|July 28, 2007
Residues Leu261, Trp264, and Phe265 account for apolipoprotein E-induced dyslipidemia and affect the formation of apolipoprotein E-containing high-density lipoproteinKonstantinos Drosatos, Kyriakos E Kypreos, Vassilis I Zannis
Vascular Pharmacology|October 13, 2009
Androgen deficiency and atherosclerosis: The lipid linkAbdulmaged M Traish, Rami Abdou, Kyriakos E Kypreos
Frontiers in Oncology|April 12, 2021
The Lipoprotein Transport System in the Pathogenesis of Multiple Myeloma: Advances and ChallengesVasileios Lazaris, Aikaterini Hatziri, Argiris Symeonidis, et al.
Biochemical Pharmacology|March 19, 2013
HDL particle functionality as a primary pharmacological target for HDL-based therapiesKyriakos E Kypreos, Spyridon Gkizas, Loukianos S Rallidis, et al.
Pageof 8